Glioblastoma (GBM) is one of the most lethal brain cancers worldwide, and there is an urgent need for development of novel therapeutic approaches. Parecoxib is a well-known cyclooxygenase-2 (COX-2) inhibitor, had already been developed for postoperative analgesia with high efficience and low adverse reaction. Recent study suggested that parecoxib potently enhances immunotherapeutic efficacy of GBM, but its effects on GBM growth, migration and invasion had never been studied before. In the present study, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and, BrdU (5-Bromo-2-deoxyUridine) incorporation assays were used to evaluate the cell proliferation of GBM cells. Wound-healing and Transwell assays were preformed to analyze GBM cell migration and invasion, respectively. The results suggested that parecoxib inhibits cell proliferation, migration and invasion of GBM cells in a dose-dependent manner. RT-qPCR (Quantitative Real-time PCR) analysis demonstrated that miRNA-29c can be significantly induced by parecoxib. Furthermore, our data suggested that miRNA-29c inhibitor can significantly attenuate parecoxib's effect on proliferation, migration and invasion of GBM. In conclusion, the present study suggested that parecoxib inhibits GBM cell proliferation, migration and invasion by up-regulating miRNA-29c.
- Received August 25, 2016.
- Accepted November 23, 2016.
- © 2016. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.